Diffusion-weighted MR imaging in liver metastases of colorectal cancer: Reproducibility and biological validation

European Radiology

Volumn 23, Issue 3, 2013, Pages 748-756

  Heijmen, Linda ^a   Ter Voert, Edwin E G W ^a   Nagtegaal, Iris D ^a   Span, Paul ^a   Bussink, Johan ^a   Punt, Cornelis J A ^b   De Wilt, Johannes H W ^a   Sweep, Fred C G J ^a   Heerschap, Arend ^a   Van Laarhoven, Hanneke W M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Diffusion weighted magnetic resonance imaging; Histopathological validation; Liver metastases; Reproducibility; Response monitoring

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; VASCULOTROPIN A;

ADULT; AGED; APOPTOSIS; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CANCER ADJUVANT THERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; METASTASIS RESECTION; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOFREQUENCY ABLATION; REPRODUCIBILITY; SYSTEMIC THERAPY;

EID: 84878556688     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-012-2654-4     Document Type: Article

References (29)

1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E (2012) European cancer mortality predictions for the year 2012. Ann Oncol 23:1044-1052
2. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244:254-259
3. Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572
4. Heijmen L, Verstappen MC, Ter Voert EE et al (2012) Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use? Crit Rev Oncol Hematol 83:194-207
5. Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622-1635
6. Yablonskiy DA, Sukstanskii AL (2010) Theoretical models of the diffusion weighted MR signal. NMR Biomed 23:661-681
7. Zhang XY, Sun YS, Tang L, Xue WC, Zhang XP (2011) Correlation of diffusion-weighted imaging data with apoptotic and proliferation indexes in CT26 colorectal tumor homografts in balb/c mouse. J Magn Reson Imaging 33:1171-1176
8. Cui Y, Zhang XP, Sun YS, Tang L, Shen L (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248:894-900
9. Dzik-Jurasz A, Domenig C, George M et al (2002) Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360:307-308
10. Mardor Y, Roth Y, Ochershvilli A et al (2004) Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia 6:136-142
11. Herneth AM, Guccione S, Bednarski M (2003) Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol 45:208-213
12. Uhl M, Saueressig U, van Buiren M et al (2006) Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol 41:618-623
13. De Vita F, Orditura M, Lieto E et al (2004) Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 100:270-278
14. Galizia G, Lieto E, Ferraraccio F et al (2004) Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 10:3490-3499
15. Hamstra DA, Galban CJ, Meyer CR et al (2008) Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26:3387-3394
16. Kim SH, Lee JY, Lee JM, Han JK, Choi BI (2011) Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer. Eur Radiol 21:2567-2574
17. Koh DM, Scurr E, Collins D et al (2007) Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 188:1001-1008
18. Mardor Y, Pfeffer R, Spiegelmann R et al (2003) Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 21:1094-1100
19. Song I, Kim CK, Park BK, Park W (2010) Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3T. AJR Am J Roentgenol 194:W477-W482
20. Desar IM, van Laarhoven HW, Hambrok T et al (2010) Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in renal cell carcinoma (RCC) by dynamic contrast enhanced MRI (DCE-MRI) and diffusion weight MRI (DWI) at 3 tesla (T). ASCO Annual Meeting, June 4-8, 2010, Chicago, IL (abstract)
21. Kim SY, Lee SS, Byun JH et al (2010) Malignant hepatic tumors: short-term reproducibility of apparent diffusion coefficients with breath-hold and respiratory-triggered diffusion-weighted MR imaging. Radiology 255:815-823
22. Rademakers SE, Rijken PF, Peeters WJ et al (2011) Parametric mapping of immunohistochemically stained tissue sections; a method to quantify the colocalization of tumor markers. Cell Oncol (Dordr) 34:119-129
23. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310
24. van Laarhoven HW, Rijpkema M, Punt CJ et al (2003) Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases. J Magn Reson Imaging 18:315-320
25. Hatt M, Cheze-Le Rest C, Aboagye EO et al (2010) Reproducibility of 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET tumor volume measurements. J Nucl Med 51:1368-1376
26. Munro AJ, Lain S, Lane DP (2005) P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 92:434-444
27. Stefanini MO, Wu FT, Mac Gabhann F, Popel AS (2010) Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res 70:9886-9894
28. Hsei V, Deguzman GG, Nixon A, Gaudreault J (2002) Complexation of VEGF with bevacizumab decreases VEGF clearance in rats. Pharm Res 19:1753-1756
29. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF (2008) Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11:109-119